Safety Alerts & Recalls
What does this mean?
The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as Etidronic Acid. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use.
Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time.
Early communication of ongoing safety review
The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as Etidronic Acid. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use.
Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time.
For more information, please visit: more information here
Visit the medication page for the following drugs:
Share your story! Tell us how MediGuard has helped you or someone you
love.
Download the MediGuard Mobile App to manage your prescription and
over-the-counter medications, for free.
Taking multiple medications puts you at risk for possible drug-drug
interactions
Monitor the medical treatment of you and your loved ones.
